Answers are grounded in this paper and cite their sources.
Human-derived exosomes show promise for hair loss treatment but may pose safety concerns, including inflammatory responses and pathogen transmission. Here, we investigated whether plant-derived exosomes, whose isolation can be standardized, and which show lower compositional complexity and no immunogenicity, represent a valid alternative. We isolated and characterized exosome-like nanovesicles from the Ashwagandha plant (Ash-ELNs), which is traditionally used to relieve stress, and pre-clinically explored their hair growth-promoting potential. Multi-omic approaches demonstrated low variations in the content of seven different Ash-ELN preparations, and cellular vesicle uptake was confirmed in human dermal fibroblasts (HDFs). In a scratch assay of human dermal papilla fibroblasts (HDPCs), Ash-ELNs significantly increased the production/secretion of the hair growth promoters VEGF-A, PLGF1, FGF2 and LIF. Application of Ash-ELNs to healthy human microdissected hair follicles significantly prolonged anagen and increased hair shaft production, while hair matrix keratinocyte proliferation and -apoptosis remained unaltered. Ash-ELNs significantly upregulated VEGF-A protein expression in the bulb mesenchyme, corroborating our in vitro results. Finally, Ash-ELNs promoted tubulogenesis in an HDF-human umbilical vein endothelial cell (HUVEC) assay, suggesting VEGF-A-induced angiogenesis as a possible mechanism underlying the anagen promoting effect of Ash-ELN. Thus, Ash-ELN treatment offers a novel adjuvant strategy or non-drug agent to reduce hair shedding.
No takes yet. Share an insight, caveat, or question.
Riche et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: